10-Q: LAVA Therapeutics to be Acquired by XOMA

LAVA Therapeutics N.V. announced a definitive agreement to be acquired by XOMA Royalty Corporation for $1.16 per share plus contingent value rights, alongside significant restructuring and program discontinuations.

Summary

• LAVA Therapeutics N.V. has entered into a Share Purchase Agreement to be acquired by XOMA Royalty Corporation for $1.16 per share in cash, plus an additional amount of cash up to $0.08 per share, and one contingent value right (CVR) per share.
• The acquisition is subject to customary conditions, including a minimum tender of 80% of shares (potentially 75%) and LAVA's closing net cash being at least $31.5 million.
• The company reported a net loss of $12.118 million for the six months ended June 30, 2025, compared to a net loss of $8.908 million for the same period in 2024.
• Revenue from contracts with customers was $0.0 million for the six months ended June 30, 2025, a significant decrease from $6.992 million in the prior year period, primarily due to no milestone payments received from Pfizer in 2025.
• Cash and cash equivalents decreased to $26.380 million as of June 30, 2025, from $35.015 million at December 31, 2024.
• Short-term investments also decreased to $29.789 million from $41.561 million over the same period.
• The company discontinued its LAVA-1207 clinical trial in December 2024 and announced the decision to discontinue its LAVA-1266 Phase 1 clinical trial and wind-down the program on August 4, 2025.
• A restructuring plan initiated in February 2025 included a workforce reduction of approximately 68% (to 11 full-time employees) and termination of lease arrangements in Utrecht and Den Bosch, incurring $3.227 million in restructuring and impairment charges for the six months ended June 30, 2025.
• The company recognized a $5.203 million gain on extinguishment of borrowings in March 2025 due to the permanent waiver of a $5.5 million Innovation Credit loan from Rijksdienst voor Ondernemend Nederland (RVO).

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to increased losses, zero revenue, and the discontinuation of key clinical programs, indicating a failure of the independent business model. While the acquisition by XOMA provides a potential exit for shareholders, the terms are modest, and the contingent value rights are highly speculative, reflecting a distressed sale rather than a growth opportunity. The extensive restructuring and workforce reduction further underscore the company's challenging position.

Positives

• The proposed acquisition by XOMA Royalty Corporation provides a potential exit for shareholders, offering a fixed cash component and contingent value rights.
• The permanent waiver of a $5.2 million loan balance from Rijksdienst voor Ondernemend Nederland (RVO) resulted in a significant non-cash gain on extinguishment of borrowings.
• The company's cash, cash equivalents, and short-term investments of $56.2 million as of June 30, 2025, are believed to be sufficient to fund operations for at least the next twelve months, especially with reduced expenses due to restructuring and program discontinuations.

Negatives

• Net loss increased to $12.118 million for the six months ended June 30, 2025, from $8.908 million in the prior year period.
• Revenue from contracts with customers dropped to $0.0 million for the six months ended June 30, 2025, compared to $6.992 million in the same period of 2024, indicating a lack of new milestone achievements.
• Cash used in operating activities significantly increased to $25.394 million for the six months ended June 30, 2025, from $9.057 million in the prior year period, reflecting a higher cash burn.
• The discontinuation of both the LAVA-1207 and LAVA-1266 clinical programs indicates a significant setback in the company's proprietary pipeline development.
• Extensive restructuring, including a 68% workforce reduction and lease terminations, highlights the company's distressed operational state prior to the acquisition.

Risks

• The proposed acquisition by XOMA is subject to conditions, including a minimum tender of 80% (or 75%) of shares and LAVA's closing net cash being at least $31.5 million, which may not be satisfied.
• Failure to complete the proposed transactions could result in significant transaction costs, diversion of management's focus, and continued business disruptions.
• The contingent value rights (CVRs) may expire valueless if no CVR Proceeds become payable from asset dispositions or Pfizer/J&J collaborations within the specified timeframe.
• Provisions in the Purchase Agreement, such as the $0.75 million termination fee, could discourage potential competing acquirers.
• Shareholder or other litigation could prevent or delay the consummation of the proposed transactions and incur additional costs.
• The announcement and pendency of the transaction could adversely affect business, financial results, and operations, including challenges in employee retention and diversion of management attention.
• If the proposed transactions are not consummated, the company may pursue other strategic alternatives, which may not be successful or on favorable terms, or may lead to dissolution and liquidation.
• In the event of dissolution and liquidation, the amount of cash available for distribution to shareholders is uncertain and depends on the timing and resolution of outstanding and contingent obligations.
• The company's ability to consummate the proposed transactions or other strategic alternatives depends on retaining remaining employees and engaging advisors, which is challenging given the significant workforce reduction.

Future Outlook

The company's future outlook is primarily centered on the proposed acquisition by XOMA Royalty Corporation, which is expected to conclude its independent operations. If the acquisition is not consummated, the company will require substantial additional funding to develop product candidates and support continuing operations, or may pursue dissolution and liquidation. The company anticipates decreased expenses and capital requirements due to ongoing strategic alternatives and winding down activities. A decision on the Pfizer buy-up option is expected as early as 2026, contingent on clinical data.

Management Comments

• Our management believes that our cash and cash equivalents and short-term investments will be sufficient to fund our operations for at least the next twelve months from the issuance date of these condensed consolidated financial statements.
• We expect our expenses and capital requirements will decrease in connection with our ongoing activities as we pursue these transactions and explore strategic alternatives for our clinical and research programs.
• Our board of directors unanimously determined that the terms of the proposed transactions under the Purchase Agreement are in the best interests of the Company and the sustainable success of our business, having considered the interests of our shareholders, employees and other relevant stakeholders.

Industry Context

This announcement reflects a broader trend in the biotechnology and pharmaceutical industry where smaller clinical-stage companies, especially those facing significant R&D costs and pipeline setbacks, seek strategic alternatives like acquisitions or mergers to maximize shareholder value and preserve capital. The discontinuation of multiple clinical programs and a substantial workforce reduction indicate the challenges of drug development and the high-risk nature of the immuno-oncology sector. The acquisition by XOMA, a royalty corporation, suggests a shift from active drug development to a more asset-monetization strategy for LAVA's remaining partnered programs.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently subject to any material legal proceedings as of June 30, 2025 or December 31, 2024.

Related Party Transactions

• The company has an agreement with Amsterdam UMC (Amsterdam UMC Agreement) from January 2017, granting an exclusive license for certain patent rights and know-how. The company is obligated to pay low single-digit tiered royalties on net sales of products covered by claims, but no royalties have been incurred or paid to date as there have been no net sales.

Stakeholder Impact

• Shareholders: Face a tender offer for acquisition, providing a cash exit and speculative contingent value rights. Risk of deal failure could lead to dissolution.
• Employees: Significant workforce reductions (approximately 68% of global workforce) due to restructuring, leading to job losses and potential morale issues for remaining staff.
• Partners (Pfizer, J&J): Collaborations continue, with potential for future milestone payments and royalties, which are now tied to the CVRs for LAVA's shareholders post-acquisition.
• Creditors: The waiver of a $5.2 million loan from RVO is positive for the company's financial position, reducing liabilities.

Next Steps

• Completion of the proposed acquisition by XOMA Royalty Corporation via tender offer.
• Wind-down of the LAVA-1266 program.
• Completion of the Restructuring Plan actions by the end of 2025.
• Decision on the Pfizer buy-up option as early as 2026, contingent on clinical data from Pfizer.

Key Dates

Recommendation

The company is undergoing a strategic acquisition by XOMA Royalty Corporation, offering a fixed cash price of $1.16 per share plus potential additional cash and contingent value rights (CVRs). For existing shareholders, holding shares to participate in the tender offer is the most logical action to realize the announced value, as the CVRs offer speculative upside. The alternative, if the deal fails, is potential dissolution and liquidation, which carries significant downside risk. For new investors, the limited upside from the fixed tender price and the speculative nature of the CVRs, coupled with the high risk if the acquisition does not close, makes it an unattractive entry point. The underlying business operations are winding down, and recent financial results show increased losses and zero revenue, reinforcing that the investment thesis is now solely tied to the acquisition's success.

Keywords

LAVA Therapeutics, XOMA Royalty Corporation, Acquisition, Tender Offer, Biotechnology, Immuno-oncology, Gammabody, Clinical Trials, LAVA-1266, LAVA-1207, Restructuring, SEC Filing, 10-Q, Contingent Value Rights, Pfizer Collaboration, Johnson & Johnson Collaboration